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Abstract: Targeted nucleases are powerful genomic tools to precisely change the target genome of
living cells, controlling functional genes with high exactness. The clustered regularly interspaced
short palindromic repeats associated protein 9 (CRISPR-Cas9) genome editing system has been
identified as one of the most useful biological tools in genetic engineering that is taken from adaptive
immune strategies for bacteria. In recent years, this system has made significant progress and it has
been widely used in genome editing to create gene knock-ins, knock-outs, and point mutations. This
paper summarizes the application of this system in various biological sciences, including medicine,
plant science, and animal breeding.
Keywords: CRISPR system; Cas proteins; agriculture; animal science; human disease
1. Introduction
Significant advancements have been made in biotechnology in recent years, and the
branch of genetic engineering is advancing at an unprecedented pace, yielding numerous
advantages. Genome editing technology has revolutionized genetic and biological re-search
via the novel ability to precisely manipulate and modify the genomes of living organisms,
and by accelerating the study of functional genomics. In recent years, different genome
editing tools have been utilized to study simple and intricate genomes [1,2]. Genome
editing technology emerged in the 1990s, and various methods have since been developed
for targeted gene editing [3,4]. In general, three systems—each with their own advantages—
have been widely used in cells and animals, including transcription activator-like effector
nuclease (TALEN), zinc finger nuclease (ZFN), and clustered regularly interspaced short
palindromic repeats (CRISPR) [3,5]. ZFNs are targetable DNA cleavage proteins with
the ability to cut DNA sequences at any location [4]. TALENs comprise double-stranded
breaks (DBs) in target sequences that trigger DNA damage response pathways that lead
to repair [4]. Despite the widespread application of these tools during 2002–2012, some
restrictions prevent their effectual use [4]. TALENs face problems with cloning large
modules in series, reduced efficiency for screening positive targeted cells, and efficient
ordered affiliate by ligase [3], whilst complexity and lack of specificity are big challenges
for ZFNs [2–4]. A powerful genome editing system called CRISPR emerged in 1987,
which became known as the greatest genetic tool of the century due to its outstanding
advantages [6]. CRISPR-Cas9 technologies took the lead over other previous methods,
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such as TALENs and ZFNs, owing to its numerous advantages, like low cost, simplicity,
high efficiency, and speed. Table 1 compares their differences [7]. In this work, a short
summary of the CRISPR system and its application has been reviewed.
Table 1. Main differences between three genome editing techniques.
Feature CRISPR-Cas TALEN ZFN
Cost Low High Low
Ease of design Simple A little complex Moderate
Specificity High Intermediate Low
Pros Modifies multiple sites in tandem Highly effective and specific Highly effective and specific
Cons PAM motif required next to target sequence Time consuming Time consuming
Multiplex genome editing High-yield multiplexing Few models Few models
2. Origin, Development, and Mechanism of the CRISPR-Cas9 System
The CRISPR was first reported by Yushizumi Ishino [8], but its biological application
was unknown at the time [3]. According to effector proteins, this system has been cate-
gorized into two main classes with six subtypes [2,9]. The type2 CRISPR-Cas9 system is
the most widely used item in the field of genome editing with three main components: a
CRISPR RNA (cRNA), an endonuclease named Cas9, and a transactivating crRNA (tracr-
RNA) [6]. This system consists of two components: (1) the Cas9 protein which can cleave
the DNA and (2) the guide RNA that distinguishes the sequence of DNA to be rectified. To
apply CRISPR-Cas9, sequences of the intended target genome are first identified. Then,
the guide RNA is tailored to recognize a particular stretch of As, Ts, Gs, and Cs in the
DNA. The guide RNA is affiliated to the DNA cutting enzyme Cas9, and then this complex
is presented to the target cells. Cas9 locates the target letter and cuts the DNA at that
point, allowing alteration of the existing genome by either modifying or adding to the
sequence (Figure 1). As such, CRISPR-Cas9 functions as a cut and paste tool for DNA
editing [10,11]. Using this technology, any genomic sequence identified by a short strand of
guide RNA can be exactly modified [12]. This system targeted the human genome for the
first time in 2013 [13–15]. To date, CRISPR-Cas9 has been commonly used to create gene
editing in plants, animal, and human samples. This technique is widely used in various
scientific fields, including medical science and therapeutics, as well as plant and animal
sciences [16–19].
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3. Ethical Issues in Genome Editing by CRISPR-Cas9 System
It is well understood in both scientific and related industries communities that CRISPR-
Cas9 technology is one of the most important findings and inventions in the present century.
However, due to its potential impact clinical applications and food safety several bioethical
issues have arisen [20,21]. Indeed, the rapid rise of CRISPR-Cas9 over other technologies
has led to new ethical issues in the various fields of bioscience [22,23]. Some bioethical
issues related to the application of CRISPR-Cas9 are presented in Table 2.
Table 2. Some of the bioethical issues and possible risks intended for the application of the CRISPR-
Cas9 system.
Organis Risks Bioethical Issues References
Bacteria Gene mutations/Gene drifts Disruption of ecological balance [20,24,25]
Plants Gene mutations/Gene drifts Disruption of ecological balance [20,26]
Animals/
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4. Applications of CRISPER-Cas9 Technology
4.1. Human Science
Recently, CRISPR-Cas9 is being employed to study various genetic diseases, such as
hemophilia [38], Duchenne muscular dystrophy [39–43], α1-antitrypsin deficiency [44,45],
hearing loss [46,47], and hematopoietic [48–50] diseases. Figure 2 shows the application
of this system in medical science. Hematologic diseases have previously been difficult
to treat via genome manipulation. Studies in recent years demonstrated that CRISPR-
Cas9 can correct genetic errors in hematopoietic stem cells that give rise to hematologic
diseases [51–55]. These can then be applied to CRISPR-Cas9-based hematopoietic stem and
progenitor cells (HSPCs) transplantation therapy. One of the most promising methods to
treat hematopoietic diseases is editing the HBB mutation with CRISPR-Cas9, and it has been
successfully carried out in patient-derived induced pluripotent stem cells (iPSCs) [56,57].
In a survey conducted by Park et al. [51], the CRISPR-Cas9 technology was used to rectify
the HBB gene mutation in HSPCs. Final outcomes inferred a decrease in the amount of
hemoglobin and sickle cells [17].
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Figure 2. Exploitation of the CRISPR-Cas9 system in the field of medicine, including infectious
diseases, tumors, and genetic diseases.
Since the CRISPR-Cas9 system originated from bacteria and acts as a bacterial im-
mune system against invasive genetic agents, it has an inherent benefit in the treatment
of bacterial and viral infection, and it is known as a new type of antiviral therapy against
various incurable viral infections. Oncogenic viruses are highly related to carcinogenesis,
including: Human papillomavirus (HPV), which could cause cervical cancer; Epstein Barr
virus (EBV) that causes nasopharyngeal carcinoma; and hepatitis B virus that triggers
liver cancer. CRISPR-Cas9 was first used to cleave HBV genomes [58]. It has previously
reported that the production of the HBV core can decrease through the HBV expression
vector [17]. Among human genetic diseases, cancer is the most common cause of death
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universally [6,17]. The tumor-suppressor genes have an important role in tumorigenesis.
They can downregulate cancer progression by controlling cell proliferation and differenti-
ation. CRISPR-Cas9 technology can target tumor-suppressor genes and restore them to
interdict the tumorigenesis [59]. Table 3 indicates the extensive application of the CRISPR-
Cas9 technique to knockout proto-oncogenes supporting the potential of this method in
various tumors.
Table 3. The use of CRISPR-Cas9 system in the treatment of different types of cancer [59].
Type Oncogene Tumor Suppressor Gene Drug-Resistance Gene
Breast SHCBP1, MIEN1, miR-27b, mi23b,HER2 exons CPEB2, ETS1, BRCA1 HER2, EGFR, ER
Prostate PCAR19, CECAM21, SENP1,miR-302/367, miR-1205 PGC1a, DEPTOR, p53, RB1
BLS-211, NANOGP8,
NANOG1
Lung IGFIR, ERBB2, RSF1, FOS, MCM4 MFN2, MiR-1205, GOT1, TP53 NRF2, MiR-1205, ER300, RSF1
Liver Plxnb1, NCAPG, CDK7, IncBRM, Nf1 BAP1, HELLS, Tp53, Traf3 NF1, MED12, ERK2
Colorectal KRAS, HPV16, Fut4, NRAS LIMCH, PTEN, SOX15 miR-139-5P, ZEB1
CRISPR-Cas9 function Knockout Activate Promote drug sensitivity
4.1.1. Clinical Trials Using CRISPR-Cas9 Technology
The United States clinical trial database [60] contains useful information on experi-
ments that have been used various genome editing tools such as ZFN, zinc finger, and
CRISPR, Cas9, Cas12, and Cas13. Clinical trials using CRISPR-based therapies are still in
their primary stages. It other words, if the treatments are safe and effective, they are likely
to be several years away from legal authorities. New possibilities in precision medicine
have arisen with the advent of CRISPR technology. Recently, many experiments are under-
way for several diseases such as several types of cancer, blood disorders, chronic infections,
eye diseases, and protein folding disorders. All CRISPR-related trials have been performed
to edit specific cells or tissues without affecting eggs or sperm; hence no DNA changes
can be transferred on to future generations during these experiments [61,62]. The first
application of CRISPR-based therapy refers to February 2019 in Germany. In this ex vivo
trial, twelve patients were treated, and seven of them have been followed for at least three
months. As a considerable result, they have observed that the patients had not needed
blood transfusions even after treatment. Recently, Hirakawa et al. [62], Frangoul et al. [63],
and Lu et al. [64] have provided a comprehensive information on application of CRISPR in
the clinical trials. Herein, we summarized some clinical trials in a complete Table (Table 4).
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Table 4. Several examples for clinical trials with genome editor of CRISPR-Cas9.
Target Gene and Effect Disease Intervention
Cas9-mediated creation of CD19 and CD20 Leukemia CAR T cells to CD19 and CD20 or CD19 and CD22
CCR5 knockout HIV Modified CD34+ hematopoietic stem cells
CD7 knockout in CD7 CAR T cells T-cell malignancies CAR T cells to CD7 and knockout of native CD7 to preventself-targeting
Correction of the hemoglobulin subunit β globulin gene β-thalassemia Ex vivo modified hematopoietic stem cells
Creation of a CD19-directed T cell Refractory B-cell malignancies CD19-directed T-cell immunotherapy
Cytokine-induced SH2 protein (CISH) knockout Metastatic gastrointestinal epithelial cancer Modified tumor-infiltrating lymphocytes
disruption of HPK1 Refractory B cell malignancies CD19-CAR modified T cells with CAR delivered by lentivirus andCas9 knockout of HPK1
Disruption of the erythroid enhancer to BCL11A gene β-thalassemia Ex vivo modified hematopoietic stem cells
Sickle cell anemia
β-thalassemia and severe sickle cell anemia Ex vivo- modified hematopoietic stem cells, 15-year follow-up study
E6 and E7 oncogene of HPV16 and HPV18 deletion HPV-related malignancy Plasmid in a gel containing a polymer to facilitate delivery
Programmed cell death protein 1 (PD-1) knockout Mesothelin positive solid tumors CAR T cells to mesothelin with added PD-1 and TCR knockout
Hormone refractory prostate cancer Modified T cells
Esophageal cancer
Metastatic non-small cell lung cancer
Stage IV bladder cancer
Metastatic renal cell carcinoma
EBV-positive, advanced stage malignancies Modified T cells selected for those targeting EBV positive cells
Mesothelin positive solid tumors CAR T cells to mesothelin with PD-1 knockout
Removal of alternative splice site in CEP290 Leber congenital amaurosis 10 ZFN-mediated removal of intronic alternative splice site in retinal cells
TCRα, TCRβ, PD-1 knockout Various malignancies Modified T cells with Cas9-mediated deletions and lentiviraltransduction of NY-ESO-1 targeted TCR
βTCRα, TCRβ, β-2 microglobin (B2M) knockout B-cell leukemia CD19-CAR modified T cells with CAR delivered by lentivirus andCas9 knockout B2M and TCR to create universal T cells
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4.1.2. Clinical Trials of the Eye Based on CRISPR-Cas9
Clinical trials of in vivo genome editors have also begun. In all trials, tissues such as
the eyes, cervix, and liver have been subjected to experiment. Cas9 was delivered to the
eye using Adeno-associated virus vectors (AAV) as a therapy for congenital amaurosis
type 10 LBA (LCA10). Because the most frequent LCA10 produces a mutation in the
intron of the Centrosomal Protein 290 gene (CEP290) and provides a new binding site
that changes the mRNA to form an early stop codon [65], it is a good candidate for the
therapy of Cas9. Leber’s congenital amaurosis 10 therapy (LCA10) is reported as the
first Cas9-related clinical trial (Table 4). This therapy employs two sgRNAs that, when
combined, cause partial deletion of the intron or in-version of the partial intron, resulting
in normal CEP290 protein production in the patient’s cells. Since the eye is an accessible
tissue and subretinal injections in mice and mammals have provided stable gene editing,
hence successful therapy may also be done in humans [65].
4.1.3. Limitations of CRISPR-Cas-Based Gene Therapy
There are many projects related to CRISPR-Cas9 for disease research, and recent
results and reports summarize the benefits of CRISPR-Cas9 [66,67]. Before employing
CRISPR/Cas9-based gene treatments in humans, their safety and efficacy should be as-
sessed and adjusted [68]. One of the main limitations of this technology is that not all
mutation sites play a protospacer adjacent Motif (PAM) role, such that target detection
depends entirely on this role. In addition, DNA damage response, delivery vehicle, editing
at off-target genomic sites, and immunogenicity are other challenges of using CRISPR-Cas9
for gene therapy. The limitations of CRISPR-Cas9 technology are mainly related to extra-
target DNA fracture formation, extra-target mutations, and PAM sequence dependence.
Off-target effects are a serious problem in genome editing trials. The CRISP-Cas9 technol-
ogy has a great chance of causing off-target alternations in human cells compared to other
editing approaches [26,28,62,69]. Mutations outside the target location can induce gene
dysfunction and, in rare cases, cell death. Choosing a suitable target locus possible during
the bioinformatics analysis phase improves the effectiveness of the CRISPR-Cas9 system.
Combining Cas9-D10A with sgRNA results in hydrolysis of one DNA strand at the target
location [70].
4.2. Plant Science
Success in plant breeding depends on trait variability as well as overall genetic vari-
ation among plant populations. Recently, yield performance and several quality-related
properties have been engineered by genome editing [71]. CRISPR-Cas9 has proved useful
in crop improvement to increase disease resistance, improve yield, improve nutrition, and
aid domestication. These advantageous genetic modifications and others will be discussed
in this section.
4.2.1. Plant Disease Resistance
Biotic stresses have usually been controlled by the spread of pathogen-resistant vari-
eties and by applying agrochemicals. However, agrochemicals can cause contamination of
the environment and negatively impact human health. Plant pathogens are also constantly
evolving and can become unresponsive to these controls. Therefore, to create pathogen
resistance in plants, resistance genes from wild species were introduced via breeding and
established genetic transformation technologies involving large genomics regions [72].
Nonetheless, given the lack of specificity of the large genomic regions being introduced,
other less-desirable traits may also be introduced using these approaches to create elite
cultivars. Conversely, the CRISPR-Cas9 system provides a more accurate approach to
genetic modification. Since first introduced to the field, it has proven to overcome several
agricultural challenges including biotic stress resistance, fungal and bacterial disease re-
sistance, and viral resistance [73]. For instance, CRISPR-Cas9 was employed to knockout
the mitogen-activated protein kinase-5 (OsMPK5) gene to enhance disease resistance in
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rice [74]. Plant viruses invade a wide range of plants and affect the fertility of crops. As
shown in Table 5, the CRISPR-Cas9 system provides a suitable context to develop resistance
against both DNA- and RNA-based plant viruses [73].
Table 5. Proven viral resistance in plants introduced via CRISPR-Cas9 against DNA and RNA viruses [73].
Virus Type of Nucleic Acid Involved Protein Plant under Attack References
Beet severe curly top virus DNA Cas9 Capsicum [75]
Bean yellow dwarf virus DNA Cas9 Oat [76]





Tomato yellow leaf curl virus DNA Cas9 Invading a number ofseeds, including tomato [78,79]
Yellowing virus RNA Cas13 Cucumber [80]
Zucchini yellow mosaic virus RNA Cas13 Cucumber [81]
Papaya ring spot mosaic virus RNA Cas13 Cucumber [82]
As the latest genome editing tool, CRISPR-Cas9 has a key potential in developing
bacterial resistance in plants. In several studies, the considerable potential for CRISPR-Cas9
technology has demonstrated to counteract crop bacterial diseases. (Table 6). For example,
mutagenesis of the ethylene-responsive factor (ERF) transcription factor gene OsERF922
using this technology enhanced resistance in rice cope with the blast disease. In another
case, researchers modified the effector-connection element in the promoter of the Lateral
Organ Boundaries-1 gene (LOB) to confer resistance to citrus bacterial canker (CBC) caused
by Xanthomanas citri subsp. in Duncan grapefruit [81].
Table 6. Three examples of exploitation of CRISPR-Cas9 to counteract crop bacterial disease.
Plant Targeted Area in Gene Disease References
Rice






the promoter of the Lateral
Organ Boundaries 1 gene
Citrus bacterial
canker (CBC) [81]
Wanjinchen oranges (CsLOB1G and CsLOB1−)alleles
Citrus bacterial
canker (CBC) [82]
4.2.2. Yield of Crop Plants
Cereal crops play a key role in human life as food primarily supplying energy. Due
to high demand for them, plant breeders have always sought ways to mass produce and
generate products with high quality. With the CRISPR-Cas9 technology, it is possible to
modify crop characteristics and improve their tolerance to adverse climate conditions and
universal threats like drought, salinity, or frost [74]. For instance, to increase tolerance to
salinity stress in rice, the O. sativa response regulator-22 gene (osRR22) was knocked-out to
achieve approximately 65% mutation in T0 lines [74]. CRISPR-Cas9 was also described to
hold potential for enhancing traits like drought or herbicide tolerance in maize [83]. As such,
three sgRNAs were designed to target the ZmTMS5 gene in maize and generate mutations
in protoplasts, which resulted in edited plants showing bi-allelic modification [74]. Some
research have shown the use of CRISPR-based genome editing in plants during the last
decade, and a few studies have documented the use of genome editing to ameliorate biotic
and abiotic stressors for crop development (Table 7).
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Table 7. Several examples of the application of CRISPR-Cas9 technology in plants against environmental stresses.
Crop Method Target Gene Stress/Trait References
A. thaliana/
N. benthamiana NHEJ dsDNA of virus (A7, B7, and C3 regions) Beet severe curly top virus resistance [75]
N. benthamiana Bean NHEJ BeYDV Yellow dwarf virus (BeYDV) resistance [76]
N. benthamiana NHEJ
ORFs and the IR
sequence
sDNA of virus
Tomato yellow leaf curl virus (TYLCV) and
Merremia mosaic virus (MeMV) [77]
Rice NHEJ OsERF922 (ethylene responsive factor) Blast Resistance [78]
Cucumber NHEJ eIF4E (eukaryotic translation initiationfactor 4E)
Cucumber vein yellowing virus (CVYV),
Zucchini
yellow mosaic virus (ZYMV), and
(PRSV-W)
[80]
A. thaliana NHEJ eIF(iso)4E Turnip mosaic virus (TuMV) resistance [84]
Rice (IR24) NHEJ OsSWEET13 Bacterial blight disease resistance [85]
Bread wheat NHEJ TaMLO-A1, TaMLO-B1, and TaMLOD1 Powdery mildewresistance [86]
Maize HDR ARGOS8 Increased grain yield under drought stress [87]
Tomato NHEJ SlMAPK3 Drought tolerance [88]
A. thaliana HDR MIR169a Drought tolerance [89]
A. thaliana NHEJ OST2 (OPEN STOMATA 2)(AHA1)
Increased stomatal closure in response to





Involved in various abiotic stress tolerance [91]
Rice NHEJ OsMPK5 Various abiotic stress tolerance and diseaseresistance [92]
Rice NHEJ/HDR OsMPK2, OsDEP1 Yield under stress [93]
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4.2.3. Genome Modification for Nutritional Improvement
As populations grow, the order for high value food crops increases [94]. The CRISPR-
Cas9 system has made it possible to improve crop value and food quality through en-
hancing their nutritional status. For example, lycopene is a plant nutrient that is widely
found in tomato with antioxidant properties and advantageous therapeutic traits. With the
success gained in expanding the amount of lycopene content in tomato, it is expected that
CRISPR-Cas9 technology may also play a key role in enhancing the micronutrient content
of plants [73]. Other examples are presented in Table 8.
Table 8. Application of CRISPR-Cas9 technology in plants for nutritional traits.
Crop Method Target Gene Stress/Trait References
Rice NHEJ 2.5604 gRNA for 12,802 genes Creating genome widemutant library [95]
Maize NHEJ ZmIPK1A ZmIPKand ZmMRP4 Phytic acid synthesis [96]
Wheat HDR TaVIT2 Fe content [97]
Soybean NHEJ GmPDS11 and GmPDS18 Carotenoid biosynthesis [98]
Tomato NHEJ Rin Fruit ripening [99]
Potato HDR ALS1 Herbicide resistance [100]
Cassava NHEJ MePDS Carotenoid biosynthesis [101]
Rice NHEJ 2.5604 gRNA for 12,802 genes Creating genome widemutant library [95]
Maize NHEJ ZmIPK1A ZmIPKand ZmMRP4 Phytic acid synthesis [96]
Wheat HDR TaVIT2 Fe content [97]
Soybean NHEJ GmPDS11 and GmPDS18 Carotenoid biosynthesis [98]
Tomato NHEJ Rin Fruit ripening [99]
Potato HDR ALS1 Herbicide resistance [100]
Cassava NHEJ MePDS Carotenoid biosynthesis [101]
4.2.4. Medicinal Plants
Medicinal plants may have significant effects in the treatment of various diseases,
and they have always been used in traditional medicines. Terpenoids, coumarins, tannins,
flavonoid, saponins, phenols, and cardiac glycosides are among the non-nutrient, bioactive,
and physiologically active chemicals carried by plants. These phytocompounds are well-
known for their health advantages. CRISPR-Cas9 could be used to modify targeted genes
in herbal plants, survey the synthesis of efficacious com-pounds, select characteristics for in-
creased yield, and advance research on biosynthetic pathways and regulatory mechanisms
now that the genomes of some medicinal plants have been fully sequenced [75].
4.3. Animal Breeding
Due to population-growth driven increasing demand, the production of animal-
derived food products, especially milk and meat, has increased worldwide. Providing
these products is vital for the health and fitness of people [102]. Genome editing technology
has made it possible to make precise changes in the animal genome to improve productivity
and disease resistance [7]. One of the genes that was first genetically modified in farm
animals was myostatin. Changes in this gene can drastically improve economic efficiency
of meat production [7]. Farm animals that have been genetically engineered, thus far,
include: pig, cattle, sheep, goat, and channel catfish [7]. Nonetheless, because of its global
economic value, multiparous nature, and comparatively short generation time, pig is the
most genetically modified livestock to date. CRISPR-Cas9 plays a key role in improvement
of livestock as the most prominent gene-editing technology today [103,104] (Figure 3).
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This method creates desired changes by either enhancing frequency of favorable
alleles or by clearing deleterious alleles [7]. CRISPR-Cas9 has not only helped to increase
animal products but also made many contributions to the field of biomedicine by producing
transgenic and cloned animals [102]. Genome editing tools, like CRISPR-Cas9 and PiggyBac
transposon, could be useful in immunology and vaccine development due to their low risk
to human health, such as preventing the transition of viruses [102].
4.3.1. Modification of Pigs for Xenotransplantation Research
The transplanting of living organs, tissues, and even living cells from one species to
another is known as xenotransplantation or heterologous transplantation. The first serious
xenotransplantation attempts were recorded in 1905, when slices of rabbit kidney were
implanted into a boy with chronic renal disease [105]. Following that, in the first two
decades of the twentieth century, many efforts to utilize organs from pigs, monkeys, and
lambs were recorded [105]. Due to their considerable evolutionary distance from humans,
pigs (Sus scrofa d mesticus) are now the best prospects for org n donation among studied
species. Indeed, this evolutionary distance reduces the probability of disease transmission
across species [106]. Indeed, in addition to this issue, the short gestation period of pigs is the
reason that they were considered as an animal model in clinical trials [107]. One of the most
promising breakthroughs in pig-to-human xenotransplantation research is the silencing of
porcine endogenous retroviruses (PERVs) and the insertion of the porcine RSAD2 gene into
the porcin Rosa26 locus. Niu et al. [16] generated pigs in which all copies of PERVs were
inactivated by CRISPR-Cas9 technology. Other examples regarding ap-plication of CRISPR
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technology can be seen in the literature, for example, Ryczek et al. [107], Niu et al. [108],
Denner [109], and Hryhorowicz et al. [110].
4.3.2. Application of CRISPR-Cas9 Technology in Insects
Most CRISPR-Cas genome editing research so far has relied on the Streptococcus pyo-
genes Cas9 nuclease, which can recognize the PAM sequence NGG [111]. Insects are the
most numerous creatures found in nature. As a result, ongoing research efforts have added
to the body of insect genomic information for species including Drosophila melanogaster
Meigen, Tribolium castaneum, Bombyx mori L., Apis mellifera L., Nasonia vitripennis Walker,
Acyrthosiphon pisum, and Plutella xylostella L. [112]. Insect uses of CRISPR-Cas9 are becom-
ing more common, namely in Drosophila melanogaster, Bombyx mori, and Aedes aegypti. This
method is not only becoming increasingly prominent in functional genomics research [113],
but it is also being used as a tool for pest bug and vector-borne disease control [113,114].
Due to its capacity to have a wide variety of genetic tools, Drosophila has been regarded
as one of the greatest insect models for the study of eukaryotic biology, including human
development and illness in insect research. Gratz et al. [115] started the Drosophila CRISPR-
Cas9 journey by deleting a 4.6 kb segment of the yellow gene using two gRNAs targeting
the 5′ and 3′ ends of the source, respectively, in 2013. CRISPR-Cas9 is also being tested in
other insect species, according to researchers (Table 9).
Table 9. Applications of CRISPR-Cas9 in insects.
Species Targeted Genes Strategy Germline TransmissionRate (%)
G1 Mutation Rate
(%) References




donor 8.1–26.7 2.7–10.4 [117]
yellow DNA INJ with donor 5.9–20.7 0.25–1.37 [115]
yellow Rapid INJ with donor 8–53 15 [118]
Bombyx mori BmBLOS2 mRNA INJ 95.5 35.6 [119]
th, re, fl, yellow-e,
kynu, ebony DNA INJ 5.7–18.9 ND [120]
Aedes aegypti ECFP mRNA INJ + DNAINJ 0 5.5 [121]
Daphnia magna eyeless mRNA INJ 18–47 8.2 [122]




frizzled mRNA INJ 18.33–90.85 ND [124]
NIJ and ND indicate injection and not determined, respectively.
5. Conclusions
The CRISPR-Cas9 technology is a new and purposeful method in genome editing that
has recently surpassed other methods due to its outstanding advantages. So that, it has
significantly contributed to all fields of life science, including medicine, plant breeding, and
animal breeding, also expanding researchers’ understanding of the basis of gene diversity
and gene editing. Given its current central role in this landscape, ongoing research will
likely focus on improving this technology further to enhance its specificity and efficiency.
Author Contributions: A.P.-A. and A.E. conceived the idea; K.T., F.K., and A.P.-A. wrote the
manuscript and prepared the figures; L.S., A.E., and K.T. collected information and prepared the
Table. A.P.-A. and P.P. revised the manuscript. All authors have read and agreed to the published
version of the manuscript.
Funding: This research received no external funding.
BioTech 2021, 10, 14 13 of 17
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Yang, G.; Huang, X. Methods and applications of CRISPR/Cas system for genome editing in stem cells. Cell Regen. 2019, 8, 33–41.
[CrossRef]
2. Manghwar, H.; Lindsey, K.; Zhang, X.; Jin, S. CRISPR/Cas System: Recent Advances and Future Prospects for Genome Editing.
Trends Plant Sci. 2019, 24, 1102–1125. [CrossRef]
3. Mirza, Z.; Karim, S. Advancements in CRISPR/Cas9 technology—focusing on cancer therapeutics and beyond. Semin. Cell Dev.
Biol. 2019, 96, 13–21. [CrossRef]
4. Mehravar, M.; Shirazi, A.; Nazari, M.; Banan, M. Mosaicism in CRISPR/Cas9-mediated genome editing. Dev. Biol. 2019, 445,
156–162. [CrossRef]
5. Abdelrahman, M.; Al-Sadi, A.M.; Pour-Aboughadareh, A.; Burritt, D.J.; Tran, L.-S.P. Genome editing using CRISPR/Cas9–targeted
mutagenesis: An opportunity for yield improvements of crop plants grown under environmental stresses. Plant Physiol. Biochem.
2018, 131, 31–36. [CrossRef] [PubMed]
6. Martinez-Lage, M.; Puig-Serra, P.; Menendez, P.; Torres-Ruiz, R.; Rodriguez-Perales, S. CRISPR/Cas9 for Cancer Therapy: Hopes
and Challenges. Biomedicines 2018, 6, 105. [CrossRef]
7. Raguz, N.; Lukic, B. Potential gain of genome editing for improved animal breeding. In Proceedings of the 55th Croatian & 15th
International Symposium on Agriculture, Vodice, Croatia, 16–21 February 2020.
8. Ishino, Y.; Shinagawa, H.; Makino, K.; Amemura, M.; Nakata, A. Nucleotide sequence of the iap gene, responsible for alkaline
phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J. Bacteriol. 1987, 169, 5429–5433.
[CrossRef] [PubMed]
9. Wright, A.V.; Nunez, J.K.; Doudna, J.A. Biology and applications of CRISPR systems: Harnessing nature’s toolbox for genome
engineering. Cell 2016, 164, 29–44. [CrossRef] [PubMed]
10. Doudna, J.A.; Charpentier, E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014, 346,
1258096. [CrossRef] [PubMed]
11. Barrangou, R.; Fremaux, C.; Deveau, H.; Richards, M.; Boyaval, P.; Moineau, S.; Romero, D.A.; Horvath, P. CRISPR provides
acquired resistance against viruses in prokaryotes. Science 2007, 315, 1709–1712. [CrossRef] [PubMed]
12. Jiang, F.; Doudna, J.A. CRISPR–Cas9 Structures and Mechanisms. Annu. Rev. Biophys. 2017, 46, 505–529. [CrossRef]
13. Cong, L.; Ran, F.A.; Cox, D.; Lin, S.; Barretto, R.; Habib, N.; Hsu, P.D.; Wu, X.; Jiang, W.; Marraffini, L.A. Multiplex genome
engineering using CRISPR/Cas systems. Science 2013, 339, 819–823. [CrossRef]
14. Mali, P.; Yang, L.; Esvelt, K.M.; Aach, J.; Guell, M.; DiCarlo, J.E.; Norville, J.E.; Church, G.M. RNA-guided human genome
engineering via Cas9. Science 2013, 339, 823–826. [CrossRef] [PubMed]
15. Jinek, M.; East, A.; Cheng, A.; Lin, S.; Ma, E.; Doudna, J. RNA-programmed genome editing in human cells. eLife 2013, 2, e00471.
[CrossRef] [PubMed]
16. Zhang, Y.; Karakikes, I. Translating genomic insights into cardiovascular medicines: Opportunities and challenges of CRISPR-Cas9.
Trends Cardiovasc. Med. 2020. [CrossRef]
17. Sun, J.-Y.; Hu, H.-B.; Cheng, Y.-X.; Lu, X.-J. CRISPR in medicine: Applications and challenges. Brief. Funct. Genom. 2020, 19,
151–153. [CrossRef]
18. Ahmad, S.; Wei, X.; Sheng, Z.; Hu, P.; Tang, S. CRISPR/Cas9 for development of disease resistance in plants: Recent progress,
limitations and future prospects. Brief. Funct. Genom. 2020, 19, 26–39. [CrossRef]
19. Tahir, T.; Ali, Q.; Rashid, M.; Malik, A. The journey of CRISPR-Cas9 from bacterial defense mechanism to a gene editing tool in
both animals and plants. Biol. Clin. Sci. Res. J. 2020, 2020, e017.
20. Hundleby, P.A.C.; Harwood, W.A. Impacts of the EU GMO regulatory framework for plant genome editing. Food Energy Secur.
2019, 8, e00161. [CrossRef]
21. Hirsch, F.; Iphofen, R.; Koporc, Z. Ethics assessment in research proposals adopting CRISPR technology. Biochem. Med. 2019, 29,
020202. [CrossRef]
22. Cai, L.; Zheng, L.A.; He, L. The forty years of medical genetics in China. J. Genet. Genom. 2018, 45, 569–582. [CrossRef] [PubMed]
23. Memi, F.; Ntokou, A.; Papangeli, I. CRISPR/Cas9 gene-editing: Research technologies, clinical applications and ethical considera-
tions. Semin. Perinatol. 2018, 42, 487–500. [CrossRef] [PubMed]
24. Rodriguez, E. Ethical issues in genome editing using Crispr/Cas9 system. J. Clin. Res. Bioeth. 2016, 7, 266.
25. Esvelt, K.M.; Smidler, A.L.; Catteruccia, F.; Church, G.M. Concerning RNA-guided gene drives for the alteration of wild
populations. eLife 2014, 3, e03401. [CrossRef]
26. Shinwari, Z.K.; Tanveer, F.; Khalil, A.T. Ethical issues regarding CRISPR-mediated genome editing. Curr. Issues Mol. Biol. 2017, 26,
103–110.
27. Polcz, S.; Lewis, A. CRISPR-Cas9 and the non-germline non-controversy. J. Law Biosci. 2016, 3, 413–425. [CrossRef]
BioTech 2021, 10, 14 14 of 17
28. Rodriguez, E. Ethical issues in genome editing for non-human organisms using CRISPR/Cas9 system. J. Clin. Res. Bioeth. 2017, 8,
10–4172. [CrossRef]
29. Eriksson, S.; Jonas, E.; Rydhmer, L.; Röcklinsberg, H. Invited review: Breeding and ethical perspectives on genetically modified
and genome edited cattle. J. Dairy Sci. 2018, 101, 1–17. [CrossRef] [PubMed]
30. Koplin, J.J. Human-animal chimeras: The moral insignificance of uniquely human capacities. Hastings Cent. Rep. 2019, 49, 23–32.
[CrossRef]
31. Degrazia, D. Human-animal chimeras, “human” cognitive capacities, and moral status. Hastings Cent. Rep. 2019, 49, 33–34.
[CrossRef]
32. de Graeff, N.; Jongsma, K.R.; Johnston, J.; Hartley, S.; Bredenoord, A.L. The ethics of genome editing in non-human animals: A
systematic review of reasons reported in the academic literature. Philos. Trans. R. Soc. B 2019, 374, 20180106. [CrossRef] [PubMed]
33. Otieno, M.O. CRISPR-Cas9 human genome editing: Challenges, ethical concerns and implications. J. Clin. Res. Bioeth. 2015, 6,
253–255.
34. Duardo-Sanchez, A. CRISPR-Cas in medicinal chemistry: Applications and regulatory concerns. Curr. Top. Med. Chem. 2017, 17,
3308–3315. [CrossRef]
35. Greene, M.; Master, Z. Ethical issues of using CRISPR technologies for research on military enhancement. J. Bioethical Inq. 2018,
15, 327–335. [CrossRef]
36. Sherkow, J.S. The CRISPR patent landscape: Past, present, and future. CRISPR J. 2018, 1, 5–9. [CrossRef]
37. Cathomen, T.; Schüle, S.; Schüßler-Lenz, M.; Abou-El-Enein, M. The human genome editing race: Loosening regulatory standards
for commercial advantage? Trends Biotechnol. 2019, 37, 120–123. [CrossRef]
38. Lyu, C.; Shen, J.; Wang, R.; Gu, H.; Zhang, J.; Xue, F.; Liu, X.; Liu, W.; Fu, R.; Zhang, L.; et al. Targeted genome engineering in
human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system. Stem Cell Res. Ther. 2018,
9, 92. [CrossRef]
39. Shimo, T.; Hosoki, K.; Nakatsuji, Y.; Yokota, T.; Obika, S. A novel human muscle cell model of Duchenne muscular dystrophy
created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping. J. Hum. Genet. 2018, 63, 365–375. [CrossRef]
40. Egorova, T.V.; Zotova, E.D.; Reshetov, D.A.; Polikarpova, A.V.; Vassilieva, S.G.; Vlodavets, D.V.; Gavrilov, A.A.; Ulianov, S.V.;
Buchman, V.L.; Deykin, A.V. CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly
identified large 430 kb deletion in the human DMD gene. Dis. Models Mech. 2019, 12. [CrossRef]
41. Long, C.; Amoasii, L.; Mireault, A.A.; McAnally, J.R.; Li, H.; Sanchez-Ortiz, E.; Bhattacharyya, S.; Shelton, J.M.; Bassel-Duby, R.;
Olson, E.N. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science
2016, 351, 400–403. [CrossRef]
42. Nelson, C.E.; Hakim, C.H.; Ousterout, D.G.; Thakore, P.I.; Moreb, E.A.; Rivera, R.M.C.; Madhavan, S.; Pan, X.; Ran, F.A.; Yan,
W.X.; et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 2016,
351, 403–407. [CrossRef]
43. Tabebordbar, M.; Zhu, K.; Cheng, J.K.W.; Chew, W.L.; Widrick, J.J.; Yan, W.X.; Maesner, C.C.; Wu, E.Y.; Xiao, R.; Ran, F.A.; et al.
In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 2016, 351, 407–411. [CrossRef]
44. Bjursell, M.; Porritt, M.J.; Ericson, E.; Taheri-Ghahfarokhi, A.; Clausen, M.; Magnusson, L.; Admyre, T.; Nitsch, R.; Mayr, L.;
Aasehaug, L.; et al. Therapeutic Genome Editing With CRISPR/Cas9 in a Humanized Mouse Model Ameliorates alpha1-
antitrypsin Deficiency Phenotype. EBioMedicine 2018, 29, 104–111. [CrossRef]
45. Song, C.-Q.; Wang, D.; Jiang, T.; O’Connor, K.; Tang, Q.; Cai, L.; Li, X.; Weng, Z.; Yin, H.; Gao, G.; et al. In Vivo Genome Editing
Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency. Hum. Gene Ther. 2018, 29, 853–860. [CrossRef]
46. Gao, X.; Tao, Y.; Lamas, V.; Huang, M.; Yeh, W.-H.; Pan, B.; Hu, Y.-J.; Hu, J.H.; Thompson, D.B.; Shu, Y.; et al. Treatment of
autosomal dominant hearing loss by in vivo delivery of genome editing agents. Naure 2018, 553, 217–221. [CrossRef]
47. György, B.; Nist-Lund, C.; Pan, B.; Asai, Y.; Karavitaki, K.D.; Kleinstiver, B.P.; Garcia, S.; Zaborowski, M.P.; Solanes, P.; Spataro,
S.; et al. Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss. Nat. Med. 2019, 25,
1123–1130. [CrossRef]
48. Xu, S.; Luk, K.; Yao, Q.; Shen, A.H.; Zeng, J.; Wu, Y.; Luo, H.-Y.; Brendel, C.; Pinello, L.; Chui, D.H.K.; et al. Editing aberrant splice
sites efficiently restores β-globin expression in β-thalassemia. Blood 2019, 133, 2255–2262. [CrossRef]
49. Canver, M.C.; Smith, E.C.; Sher, F.; Pinello, L.; Sanjana, N.; Shalem, O.; Chen, D.D.; Schupp, P.G.; Vinjamur, D.; Garcia, S.; et al.
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature 2015, 527, 192–197. [CrossRef]
50. Wu, Y.; Zeng, J.; Roscoe, B.P.; Liu, P.; Yao, Q.; Lazzarotto, C.R.; Clement, M.K.; Cole, M.; Luk, K.; Baricordi, C.; et al. Highly
efficient therapeutic gene editing of human hematopoietic stem cells. Nat. Med. 2019, 25, 776–783. [CrossRef]
51. Park, S.H.; Lee, C.M.; Dever, D.P.; Davis, T.H.; Camarena, J.; Srifa, W.; Zhang, Y.; Paikari, A.; Chang, A.K.; Porteus, M.H.; et al.
Highly efficient editing of the beta-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell
disease. Nucleic Acids Res. 2019, 47, 7955–7972. [CrossRef]
52. Castaño, J.; Herrero, A.B.; Bursen, A.; González, F.; Marschalek, R.; Gutierrez, N.; Menendez, P. Expression of MLL-AF4 or
AF4-MLL fusions does not impact the efficiency of DNA damage repair. Oncotarget 2016, 7, 30440–30452. [CrossRef]
53. Reimer, J.; Knoess, S.; Labuhn, M.; Charpentier, E.M.; Goehring, G.; Schlegelberger, B.; Klusmann, J.-H.; Heckl, D. CRISPRCas9-
induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo. Haematologica 2017,
102, 1558–1566. [CrossRef]
BioTech 2021, 10, 14 15 of 17
54. Heckl, D.; Kowalczyk, M.S.; Yudovich, D.; Belizaire, R.; Puram, R.V.; McConkey, M.E.; Thielke, A.; Aster, J.C.; Regev, A.; Ebert,
B.L. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing.
Nat. Biotechnol. 2014, 32, 941–946. [CrossRef]
55. Shi, J.; Wang, E.; Milazzo, J.P.; Wang, Z.; Kinney, J.B.; Vakoc, C.R. Discovery of cancer drug targets by CRISPR-Cas9 screening of
protein domains. Nat. Biotechnol. 2015, 33, 661–667. [CrossRef]
56. Xu, P.; Tong, Y.; Liu, X.-Z.; Wang, T.-T.; Cheng, L.; Wang, B.-Y.; Lv, X.; Huang, Y.; Liu, D.-P. Both TALENs and CRISPR/Cas9
directly target the HBB IVS2–654 (C > T) mutation in β-thalassemia-derived iPSCs. Sci. Rep. 2015, 5, 12065. [CrossRef]
57. Antony, J.S.; Latifi, N.; Haque, A.K.M.A.; Lamsfus-Calle, A.; Daniel-Moreno, A.; Graeter, S.; Baskaran, P.; Weinmann, P.; Mezger,
M.; Handgretinger, R.; et al. Gene correction of HBB mutations in CD34+ hematopoietic stem cells using Cas9 mRNA and ssODN
donors. Mol. Cell. Pediatrics 2018, 5, 9. [CrossRef]
58. Lin, S.-R.; Yang, H.-C.; Kuo, Y.-T.; Liu, C.-J.; Yang, T.-Y.; Sung, K.-C.; Lin, Y.-Y.; Wang, H.-Y.; Wang, C.-C.; Shen, Y.-C.; et al. The
CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol. Ther. Nucleic Acids. 2014, 3, e186.
[CrossRef]
59. Hazafa, A.; Mumtaz, M.; Farooq, M.F.; Bilal, S.; Chaudhry, S.N.; Firdous, M.; Naeem, H.; Ullah, M.O.; Yameen, M.; Mukhtiar, M.S.;
et al. CRISPR/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future
directions. Life Sci. 2020, 263, 118525. [CrossRef]
60. U.S. National Library of Medicine. Available online: https://clinicaltrials.gov/ (accessed on 22 May 2021).
61. He, S. The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancer. Signal
Transduct. Target. Ther. 2020, 5, 168. [CrossRef]
62. Hirakawa, M.P.; Krishnakumar, R.; Timlin, J.A.; Carney, J.P.; Butler, K.S. Gene editing and CRISPR in the clinic: Current and
future perspectives. Biosci. Rep. 2020, 40, BSR20200127. [CrossRef]
63. Frangoul, H.; Altshuler, D.; Cappellini, M.D.; Chen, Y.-S.; Domm, J.; Eustace, B.K.; Foell, J.; De La Fuente, J.; Grupp, S.;
Handgretinger, R.; et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. N. Engl. J. Med. 2021, 384, 252–260.
[CrossRef]
64. Lu, Y.; Xue, J.; Deng, T.; Zhou, X.; Yu, K.; Deng, L.; Huang, M.; Yi, X.; Liang, M.; Wang, Y.; et al. Safety and feasibility of
CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat. Med. 2020, 26, 732–740. [CrossRef]
65. Maeder, M.L.; Stefanidakis, M.; Wilson, C.J.; Baral, R.; Barrera, L.A.; Bounoutas, G.S.; Bumcrot, D.; Chao, H.; Ciulla, D.M.; DaSilva,
J.A.; et al. Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat. Med. 2019,
25, 229–233. [CrossRef]
66. Molla, K.A.; Yang, Y. CRISPR/Cas-Mediated Base Editing: Technical Considerations and Practical Applications. Trends Biotechnol.
2019, 37, 1121–1142. [CrossRef]
67. Knott, G.J.; Doudna, J.A. CRISPR-Cas guides the future of genetic engineering. Science 2018, 361, 866. [CrossRef] [PubMed]
68. Rich, K.; Terry, S.F. CRISPR-Cas9: New Heights, New Hesitations. Genet. Test. Mol. Biomark. 2018, 22, 635–636. [CrossRef]
[PubMed]
69. Fu, Y.; Foden, J.A.; Khayter, C.; Maeder, M.L.; Reyon, D.; Joung, J.K.; Sander, J.D. High-frequency off-target mutagenesis induced
by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 2013, 31, 822–826. [CrossRef]
70. Cui, Y.; Liao, X.; Peng, S.; Tang, T.; Huang, C.; Yang, C. OffScan: A universal and fast CRISPR off-target sites detection tool. BMC
Genom. 2020, 21, 872. [CrossRef]
71. Jung, C.; Capistrano-Gossmann, G.; Braatz, J.; Sashidhar, N.; Melzer, S. Recent developments in genome editing and applications
in plant breeding. Plant Breed. 2018, 137, 1–9. [CrossRef]
72. Wang, F.; Wang, C.; Liu, P.; Lei, C.; Hao, W.; Gao, Y.; Liu, Y.G.; Zhao, K. Enhanced Rice Blast Resistance by CRISPR/Cas9-Targeted
Mutagenesis of the ERF transcription factor gene OsERF922. PLoS ONE 2016, 11, e0154027. [CrossRef]
73. Pillay, M. Genome Editing Technologies for Crop Improvement. In Quantitative Genetics, Genomics and Plant Breeding, 2nd ed.;
CABI: Boston, MA, USA, 2020; pp. 33–44.
74. Hillary, V.E.; Ceasar, S.A. Application of CRISPR/Cas9 Genome Editing System in Cereal Crops. Open Biotechnol. J. 2019, 13,
173–179. [CrossRef]
75. Ji, X.; Zhang, H.; Zhang, Y.; Wang, Y.; Gao, C. Establishing a CRISPR–Cas-like immune system conferring DNA virus resistance in
plants. Nat. Plants 2015, 1, 15144. [CrossRef]
76. Baltes, N.J.; Hummel, A.W.; Konecna, E.; Cegan, R.; Bruns, A.N.; Bisaro, D.M.; Voytas, D.F. Conferring resistance to geminiviruses
with the CRISPR–Cas prokaryotic immune system. Nat. Plants 2015, 1, 15145. [CrossRef]
77. Aman, R.; Ali, Z.; Butt, H.; Mahas, A.; Aljedaani, F.; Khan, M.Z.; Ding, S.; Mahfouz, M. RNA virus interference via CRISPR/Cas13a
system in plants. Genome Biol. 2018, 19, 1. [CrossRef]
78. Ali, Z.; Abulfaraj, A.; Idris, A.; Ali, S.; Tashkandi, M.; Mahfouz, M.M. CRISPR/Cas9-mediated viral interference in plants. Genome
Biol. 2015, 16, 238. [CrossRef]
79. Mahas, A.; Mahfouz, M. Engineering virus resistance via CRISPR–Cas systems. Curr. Opin. Virol. 2018, 32, 1–8. [CrossRef]
80. Chandrasekaran, J.; Brumin, M.; Wolf, D.; Leibman, D.; Klap, C.; Pearlsman, M.; Sherman, A.; Arazi, T.; Gal-On, A. Development
of broad virus resistance in non-transgenic cucumber using CRISPR/Cas9 technology. Mol. Plant Pathol. 2016, 17, 1140–1153.
[CrossRef]
BioTech 2021, 10, 14 16 of 17
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